Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.

Item

http://www.wikidata.org/entity/Q41877898

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Nature of action of Sitaglipti ...... inhibitor in diabetic animals.

@en

type

Item

label

Nature of action of Sitaglipti ...... inhibitor in diabetic animals.

@en

prefLabel

Nature of action of Sitaglipti ...... inhibitor in diabetic animals.

@en

P1476

Nature of action of Sitaglipti ...... inhibitor in diabetic animals.

@en

P2093

Abhijit Ray

http://www.w3.org/2001/XMLSchema#string

Geetavani Rayasam

http://www.w3.org/2001/XMLSchema#string

Jitendra Sattigeri

http://www.w3.org/2001/XMLSchema#string

Joseph A Davis

http://www.w3.org/2001/XMLSchema#string

Sachin Sethi

http://www.w3.org/2001/XMLSchema#string

Shivani Mittra

http://www.w3.org/2001/XMLSchema#string

Shuchita Singh

http://www.w3.org/2001/XMLSchema#string

Subhasis Roy

http://www.w3.org/2001/XMLSchema#string

Vinay Bansal

http://www.w3.org/2001/XMLSchema#string

P2860

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.

Fatty acid receptors as new therapeutic targets for diabetes.

TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders.

TGR5-mediated bile acid sensing controls glucose homeostasis

P304

229-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0253-7613.68425

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20927248

http://www.w3.org/2001/XMLSchema#string

P932

2941613

http://www.w3.org/2001/XMLSchema#string